Retirement Planning Co of New England Inc. Invests $289,000 in Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• Retirement Planning Co of New England Inc. invested approximately $289,000 in Zimmer Biomet Holdings by acquiring 2,552 shares in the first quarter, reflecting growing interest from institutional investors.
• Wall Street analysts have mixed ratings for Zimmer Biomet, with forecasts suggesting a price range of $95.00 to $115.00 based on recent reports, while the stock maintains an average target price of $111.44.
• Zimmer Biomet announced a quarterly dividend of $0.24 per share, which will be paid on October 31, representing a yield of 0.9% and a payout ratio of 23.36%.

Retirement Planning Co of New England Inc. purchased a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 2,552 shares of the medical equipment provider's stock, valued at approximately $289,000.

Other institutional investors also recently made changes to their positions in the company. OneDigital Investment Advisors LLC acquired a new position in shares of Zimmer Biomet in the first quarter worth $269,000. Keybank National Association OH raised its holdings in shares of Zimmer Biomet by 61.2% in the first quarter. Keybank National Association OH now owns 14,315 shares of the medical equipment provider's stock worth $1,620,000 after acquiring an additional 5,434 shares during the last quarter. Envestnet Asset Management Inc. raised its holdings in shares of Zimmer Biomet by 26.4% in the first quarter. Envestnet Asset Management Inc. now owns 316,308 shares of the medical equipment provider's stock worth $35,800,000 after acquiring an additional 66,114 shares during the last quarter. Kingswood Wealth Advisors LLC raised its holdings in shares of Zimmer Biomet by 20.0% in the first quarter. Kingswood Wealth Advisors LLC now owns 2,605 shares of the medical equipment provider's stock worth $295,000 after acquiring an additional 435 shares during the last quarter. Finally, QRG Capital Management Inc. raised its holdings in shares of Zimmer Biomet by 13.9% in the first quarter. QRG Capital Management Inc. now owns 6,775 shares of the medical equipment provider's stock worth $767,000 after acquiring an additional 827 shares during the last quarter. 88.89% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, insider Sang Yi sold 1,000 shares of the business's stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $95.00, for a total transaction of $95,000.00. Following the completion of the sale, the insider owned 20,424 shares of the company's stock, valued at approximately $1,940,280. The trade was a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.70% of the company's stock.

Zimmer Biomet Trading Down 0.0%

ZBH stock traded down $0.02 during trading on Wednesday, reaching $104.99. 1,079,565 shares of the stock traded hands, compared to its average volume of 1,540,885. The business's 50 day moving average price is $97.88 and its 200-day moving average price is $99.58. Zimmer Biomet Holdings, Inc. has a 52-week low of $89.22 and a 52-week high of $116.56. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96. The firm has a market capitalization of $20.80 billion, a PE ratio of 25.55, a P/E/G ratio of 2.09 and a beta of 0.68.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.98 by $0.09. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The firm had revenue of $2.08 billion during the quarter, compared to the consensus estimate of $2.06 billion. During the same quarter in the previous year, the business earned $2.01 earnings per share. The firm's quarterly revenue was up 7.0% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Zimmer Biomet's payout ratio is 23.36%.

Wall Street Analysts Forecast Growth

ZBH has been the subject of several analyst reports. Canaccord Genuity Group dropped their target price on Zimmer Biomet from $115.00 to $101.00 and set a "hold" rating for the company in a research note on Monday, May 12th. Robert W. Baird dropped their target price on Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. Stifel Nicolaus set a $115.00 target price on Zimmer Biomet and gave the company a "buy" rating in a research note on Tuesday, May 6th. UBS Group upped their target price on Zimmer Biomet from $91.00 to $96.00 and gave the company a "sell" rating in a research note on Friday, August 8th. Finally, JMP Securities dropped their target price on Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating for the company in a research note on Wednesday, May 7th. Nine analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Zimmer Biomet currently has a consensus rating of "Hold" and an average price target of $111.44.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.